文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

纳曲酮治疗 HIV 相关酒精使用障碍的有效性：系统评价。

Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.

机构信息

Substance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

出版信息

Subst Abuse Treat Prev Policy. 2020 Mar 18;15(1):24. doi: 10.1186/s13011-020-00266-6.

DOI:10.1186/s13011-020-00266-6
PMID:32188486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7081595/
Abstract

BACKGROUND: Because alcohol use disorders (AUDs) in patients living with HIV/AIDS are associated with a reduction in therapeutic outcomes and increases the risk of morbidity/mortality, finding an appropriate pharmacotherapy treatment for this disorder is necessary. OBJECTIVES: This systematic review contains studies that examine the effects of pharmacological intervention (oral naltrexone (NTX) or injectable extended-release naltrexone (XR-NTX)) on the persons living with HIV and AUDs. METHODS: A systematic literature search using three electronic databases including Pubmed Medline, Scopus and the Cochrane Library and Google Scholar was conducted and includes articles published from 1995 to 2019. Records were collected by searching relevant keywords and those that meet the inclusion/exclusion criteria are included. RESULTS: Overall, in this systematic review, the results of 7 relevant studies including pilot and randomized controlled/clinical trials were summarized and reviewed. Among selected records 2 of these assessed the efficacy of NTX and 5 tested the XR-NTX effectiveness in treating AUDs among persons living with HIV (PLH). In summary, with some expectations, NTX and XR-NTX administration in persons living with HIV and AUDs led to reduced alcohol use, improved viral suppression, unchanged ART adherence and has no significant adverse events. CONCLUSION: The findings of this systematic review suggest the beneficial effects and safety of the NTX and XR-NTX for treating AUDs in PLH. Further studies are needed in the future to focus on the treatment of AUDs in people living with HIV.

摘要

背景：由于艾滋病毒/艾滋病患者的酒精使用障碍（AUD）与治疗效果降低和发病率/死亡率增加有关，因此有必要为这种疾病寻找适当的药物治疗。

目的：本系统评价包含研究，这些研究检查了药物干预（口服纳曲酮（NTX）或注射延长释放纳曲酮（XR-NTX））对艾滋病毒感染者和 AUD 患者的影响。

方法：使用包括 Pubmed Medline、Scopus 和 Cochrane 图书馆以及 Google Scholar 在内的三个电子数据库进行了系统的文献检索，并收录了 1995 年至 2019 年发表的文章。通过搜索相关关键词收集记录，并收录符合纳入/排除标准的记录。

结果：总的来说，在本系统评价中，总结和回顾了 7 项相关研究（包括试点和随机对照/临床试验）的结果。在所选择的记录中，有 2 项评估了 NTX 的疗效，5 项测试了 XR-NTX 在治疗 HIV 感染者（PLH）AUDs 中的有效性。总的来说，NTX 和 XR-NTX 在治疗 HIV 感染者和 AUDs 方面的使用带来了一些预期的效果，包括减少饮酒、改善病毒抑制、不改变抗逆转录病毒治疗（ART）的依从性，且没有显著的不良反应。

结论：本系统评价的结果表明，NTX 和 XR-NTX 治疗 PLH 的 AUDs 具有有益效果和安全性。未来需要进一步研究，重点关注治疗 HIV 感染者的 AUDs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a5d/7081595/57efa1c58abe/13011_2020_266_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a5d/7081595/57efa1c58abe/13011_2020_266_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a5d/7081595/57efa1c58abe/13011_2020_266_Fig1_HTML.jpg

相似文献

[1]
Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.

Subst Abuse Treat Prev Policy. 2020-3-18

[2]
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.

Addiction. 2017-6

[3]
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.

Drug Alcohol Depend. 2017-5-1

[4]
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).

Contemp Clin Trials. 2019-4-12

[5]
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.

J Acquir Immune Defic Syndr. 2018-9-1

[6]
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.

Drug Alcohol Depend. 2015-12-1

[7]
Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Addiction. 2018-3-24

[8]
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.

J Acquir Immune Defic Syndr. 2018-5-1

[9]
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.

AIDS Behav. 2019-1

[10]
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.

J Subst Abuse Treat. 2014-7

引用本文的文献

[1]
Effect of a brief alcohol counselling intervention on HIV viral suppression and alcohol use among persons with HIV and unhealthy alcohol use in Uganda and Kenya: a randomized controlled trial.

J Int AIDS Soc. 2023-12

[2]
Alcohol Prevention in Urgent and Emergency Care (APUEC): Development and Evaluation of Workforce Digital Training on Screening, Brief Intervention, and Referral for Treatment.

Int J Environ Res Public Health. 2023-11-7

[3]
Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.

Int J Environ Res Public Health. 2023-1-19

[4]
Alcohol Use and the Risk of Communicable Diseases.

Nutrients. 2021-9-23

[5]
Current Interventions for People Living with HIV Who Use Alcohol: Why Gender Matters.

Curr HIV/AIDS Rep. 2021-8

[6]
Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Patient Prefer Adherence. 2021-5-18

[7]
Decreased Alcohol Consumption in an Implementation Study of Computerized Brief Intervention among HIV Patients in Clinical Care.

AIDS Behav. 2021-12

[8]
The Role of Alcohol-Related Behavioral Research in the Design of HIV Secondary Prevention Interventions in the Era of Antiretroviral Therapy: Targeted Research Priorities Moving Forward.

AIDS Behav. 2021-12

本文引用的文献

[1]
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.

AIDS Behav. 2019-1

[2]
Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving Healthcare.

AIDS Behav. 2019-1

[3]
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.

J Acquir Immune Defic Syndr. 2018-9-1

[4]
Addressing unhealthy alcohol use among people living with HIV: recent advances and research directions.

Curr Opin Infect Dis. 2018-2

[5]
Effectiveness of extended release naltrexone to reduce alcohol cravings and use behaviors during treatment and at follow-up.

J Subst Abuse Treat. 2017-11-10

[6]
Naltrexone in the Treatment of Broadly Defined Behavioral Addictions: A Review and Meta-Analysis of Randomized Controlled Trials.

Eur Addict Res. 2017-9-7

[7]
Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results.

Contemp Clin Trials. 2017-9

[8]
Alcohol use disorders among people living with HIV/AIDS in Southern Brazil: prevalence, risk factors and biological markers outcomes.

BMC Infect Dis. 2017-4-11

[9]
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.

Drug Alcohol Depend. 2017-5-1

[10]
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.

Addiction. 2017-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索